Back to search

Ireland· IE-PA-EU/1/17/1215/001

Fotivda 890 microgram hard capsules

A tivozanib product containing tivozanib, registered in Ireland by EUSA Pharma (Netherlands) B.V..

ATC L01XE34

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedFotivda 890 microgram hard capsulesATCL01XE34REGISTER NO.IE-PA-EU/1/17/1215/001PACKS LISTED1CHECKEDSeptember 28, 2026

The record

At a glance

HPRA (Ireland)
Active substance
Tivozanib
Manufacturer
EUSA Pharma (Netherlands) B.V.
Country
Ireland (IE)
ATC code
L01XE34
ATC class
Tivozanib
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/17/1215/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for tivozanib.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Tivozanib · interactions on record

7 records

  • 3 severe
  • 4 moderate

Most severe, free to view

  • PhenobarbitalN03AA02severe
  • PhenobarbitalN05CA24severe
  • Hyperici herbaN06AX25severe
  • RiociguatC02KX05moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tivozanib in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tivozanib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Fotivda
  • Liechtenstein · Fotivda
  • Norway · Fotivda

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/62c8c4b6-d4e4-4f32-9884-5186828f5385
GET /v1/drugs/62c8c4b6-d4e4-4f32-9884-5186828f5385?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01XE",
    "L01XE34"
  ],
  "strength": null,
  "pa_number": "EU/1/17/1215/001",
  "substances": [
    "Tivozanib"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "24/08/2017",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about tivozanib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.